<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01064596</url>
  </required_header>
  <id_info>
    <org_study_id>0908104</org_study_id>
    <secondary_id>2009-016417-15</secondary_id>
    <nct_id>NCT01064596</nct_id>
  </id_info>
  <brief_title>Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery</brief_title>
  <official_title>Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After bariatric surgery , thromboembolics complications are major cause of mortality.
      However, in obese patients, thromboprophylaxia is a controversy. Fondaparinux' efficacy is
      superior to HBPM, and is a good treatment for this population. Pharmacokinetics information
      with Fondaparinux in this population are rare.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We proposed a bicentric study cohort of obese patients (BMI &gt; 40 kg/m2) treated by 1 day
      injection of Fondaparinux 2.5 mg after bypass surgery. Anti-Xa activity of Fondaparinux will
      be measured 4 times during hospitalisation for each patient to realise a pharmacokinetic
      modelisation of Fondaparinux. Haemorrhage and thromboembolics events will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate pharmacodynamics parameters of fondaparinux based on anti-Xa activity estimated by a non linear model at mixed effect of obese morbid patients following a bariatric surgery</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence of symptomatic venous thromboembolics events (DVT and PE) between D5 and D10 and at 1month ± 10 days</measure>
    <time_frame>D5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence of major and clinically significative bleeding between D5 and D10 and at 1 month ± 10 days</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Morbid Obesity</condition>
  <condition>Obesity</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>blood sample</arm_group_label>
    <description>Patient with 4 blood samples to measure anti-Xa activity</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery</description>
    <arm_group_label>blood sample</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      4 blood samples to measure anti-Xa activity
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        obesity patients who need a bariatric surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  requiring a bariatric surgery

          -  requiring an antithrombotics prophylaxis

          -  having a morbid obesity based on a BMI &gt;40 kg/m2

          -  having signed the inform consent form

        Exclusion Criteria:

          -  contra-indication to fondaparinux

          -  history of heparin induced thrombopenia (HIT)

          -  platelets &lt; 100 G/l

          -  requiring an effective antithrombotic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick MISMETTI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de la Mutualiste</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>February 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2010</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>fondaparinux</keyword>
  <keyword>surgery</keyword>
  <keyword>anti-Xa activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

